Scarica l'app Stockscreener
1.20
0.21%
-0.00
Precedente Chiudi:
$1.20
Aprire:
$1.2
Volume 24 ore:
31,847
Relative Volume:
0.06
Capitalizzazione di mercato:
$2.75M
Reddito:
$35.75M
Utile/perdita netta:
$11.57M
Rapporto P/E:
-0.3152
EPS:
-3.8069
Flusso di cassa netto:
$-26.25M
1 W Prestazione:
-26.53%
1M Prestazione:
-41.01%
6M Prestazione:
-79.42%
1 anno Prestazione:
-92.50%
Intervallo 1D:
$1.18
$1.23
Intervallo di 1 settimana:
$1.1758
$1.72
Portata 52W:
$1.1758
$15.33
Redhill Biopharma Ltd Adr Stock (RDHL) Company Profile
Confronta RDHL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
1.20 | 2.75M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
ZTS
Zoetis Inc
|
150.19 | 65.61B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.20 | 44.72B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.455 | 43.39B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.55 | 17.64B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
289.23 | 13.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Redhill Biopharma Ltd Adr Stock (RDHL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-08-31 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-18 | Iniziato | H.C. Wainwright | Buy |
| 2020-09-11 | Iniziato | BTIG Research | Buy |
| 2019-07-12 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2019-03-12 | Aggiornamento | WBB Securities | Speculative Buy → Buy |
| 2018-01-26 | Iniziato | Nomura | Buy |
| 2017-10-06 | Iniziato | Seaport Global Securities | Buy |
| 2017-10-04 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-24 | Reiterato | FBR & Co. | Outperform |
| 2016-07-27 | Reiterato | FBR Capital | Outperform |
| 2015-09-29 | Iniziato | Nomura | Buy |
| 2015-07-29 | Reiterato | ROTH Capital | Buy |
| 2015-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-15 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Redhill Biopharma Ltd Adr Borsa (RDHL) Ultime notizie
Redhill Biopharma stock soars after FDA provides positive pathway for Crohn’s drug - Investing.com India
Taking the lead: Redhill Biopharma Ltd. ADR (RDHL) - Sete News
The time has not yet come to remove your chips from the table: Hertz Global Holdings Inc (HTZ) - Sete News
A significant driver of top-line growth: Alexandria Real Estate Equities Inc (ARE) - Sete News
Redhill Biopharma Ltd. ADR [RDHL] Insider Activity: An Update for Investors - knoxdaily.com
RedHill Biopharma faces Nasdaq non-compliance issue - Investing.com
RedHill Biopharma faces Nasdaq non-compliance issue By Investing.com - Investing.com India
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - PR Newswire
Redhill Biopharma stock hits 52-week low at $1.72 amid market challenges - Investing.com
Redhill Biopharma stock hits 52-week low at $2.47 amid steep annual decline - Investing.com
RedHill Biopharma targets UK approval for H. pylori therapy - Investing.com India
RedHill Biopharma targets UK approval for H. pylori therapy By Investing.com - Investing.com South Africa
Redhill Biopharma Ltd. ADR (RDHL)’s Stock Price Falls Due To Weak Fundamental Momentum - Marketing Sentinel
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline By Investing.com - Investing.com South Africa
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com
What Did We Note About Insider Trading At Redhill Biopharma Ltd. ADR (NASDAQ: RDHL)? - Stocks Register
Hyloris secures global rights to RedHill’s RHB-102 - Investing.com India
Redhill Biopharma stock hits 52-week low at $4.79 - Investing.com India
Earnings call transcript: RedHill Biopharma Q1 2022 sees revenue dip - Investing.com
RedHill tests opaganib with Bayer's drug in prostate cancer study By Investing.com - Investing.com South Africa
RedHill tests opaganib with Bayer's drug in prostate cancer study - Investing.com India
RedHill stock rises on expanded Medicare coverage By Investing.com - Investing.com South Africa
RedHill wins $8 million judgment in New York court - Investing.com
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
symbol__ Stock Quote Price and Forecast - CNN
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR.com
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. - Barchart.com
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds - Barchart.com
RedHill Biopharma to Implement ADS Ratio Change to 1:400 By Investing.com - Investing.com India
Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com
Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment - PR Newswire UK
Cathie Wood Predictions 2022 - New Trader U
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire
AstraZeneca divestment of Movantik to RedHill Biopharma completed - AstraZeneca
RedHill Biopharma to Focus Commercial Efforts on Talicia® - GlobeNewswire
RedHill Biopharma: TALICIA Launch For H. Pylori In Sight - Investing.com
RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon - Seeking Alpha
RedHill Biopharma files for further Nasdaq offering - גלובס
Redhill Biopharma (RDHL) Stock Price, News & Analysis - MarketBeat
Redhill Biopharma Ltd Adr Azioni (RDHL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
0.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):